These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16640226)

  • 1. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
    Mitrović Z; Aurer I
    Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for the treatment of diffuse large B-cell lymphomas.
    Held G; Pöschel V; Pfreundschuh M
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
    Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
    Naparstek E
    Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in indolent lymphoma: the single-agent pivotal trial.
    McLaughlin P; Hagemeister FB; Grillo-López AJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):79-87. PubMed ID: 10561022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and phase I and II trials of rituximab.
    Maloney DG
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):74-8. PubMed ID: 10561021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal antibody therapy for malignant lymphoma].
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Med Klin (Munich); 2005 Jan; 100(1):14-24. PubMed ID: 15654538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab and hematological malignancy].
    Hatake K; Mishima Y; Terui Y
    Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and safety of rituximab (MabThera).
    Kimby E
    Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empowering targeted therapy: lessons from rituximab.
    Olszewski AJ; Grossbard ML
    Sci STKE; 2004 Jul; 2004(241):pe30. PubMed ID: 15252219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
    Mayer J; Navrátil M; Vásová J; Vorlícek J
    Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in immunotherapy rituximab.
    El-Habbash MM; Alwindi AM
    Saudi Med J; 2007 Nov; 28(11):1635-44. PubMed ID: 17965780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
    Impellizeri JA; Howell K; McKeever KP; Crow SE
    Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.